Cancer rates, medical comorbidities, and treatment modalities in the oldest patients

John E. Zeber, Laurel A. Copeland, Brandon J. Hosek, Anand B. Karnad, Valerie A. Lawrence, Sandra E. Sanchez-Reilly

Producción científica: Review articlerevisión exhaustiva

49 Citas (Scopus)


Cancer disproportionately afflicts older patients, with 56% of incident diagnoses and 71% of deaths occurring in this population. Yet little is known about the "oldest of the old", oncology patients underrepresented in clinical trials. We examined elderly veterans diagnosed with lung, colorectal, prostate or head-neck cancer in 2005 (n = 194,797), analyses comparing treatment receipt by age group, 70-84 versus 85-115. Treatment was more common among younger elders, including surgery (1.3% versus 0.6%), chemotherapy (2.1% versus 0.8%) and radiation (1.7% versus 0.7%). Differences were sharper for certain cancers, e.g., chemotherapy for lung (9.0% versus 2.9%), or colorectal surgery (5.8% versus 3.4%). Cancer prevalence is high among elders yet treatment rates appear extremely low, despite evidence of well-tolerated treatment. Toxicity concerns and comorbidities may inhibit pursuit of definitive treatment. As we reconcile definitions of 'elderly' with appropriate treatment options, compassionate care requires identifying geriatric oncology guidelines that improve survival and quality of life.

Idioma originalEnglish (US)
Páginas (desde-hasta)237-242
Número de páginas6
PublicaciónCritical Reviews in Oncology/Hematology
EstadoPublished - sept 2008

ASJC Scopus subject areas

  • Hematology
  • Oncology


Profundice en los temas de investigación de 'Cancer rates, medical comorbidities, and treatment modalities in the oldest patients'. En conjunto forman una huella única.

Citar esto